Side-by-side comparison of AI visibility scores, market position, and capabilities
KRX: 005930 Samsung Electronics at ~$228B revenue 2024 with record Q1 2025; world's largest memory chip maker and 720M OLED panels competing with TSMC, SK Hynix, and Apple across semiconductor, display, and mobile markets.
Samsung Electronics Co., Ltd. is a Suwon, South Korea-based global technology conglomerate — listed on the Korea Stock Exchange (KRX: 005930) and the world's largest manufacturer of memory semiconductors (DRAM, NAND flash), display panels (OLED and LCD), and smartphones — generating KRW 300.9 trillion (~$228 billion USD) in revenue in fiscal year 2024, with Q1 2025 revenue of KRW 79.14 trillion (an all-time quarterly record), driven by semiconductor division revenue of $96.9 billion (48% of total revenue), Galaxy S25 smartphone sales, and 720 million OLED panels shipped in 2024. The flagship subsidiary of the Samsung Group chaebol (founded by Lee Byung-chul in 1938), Samsung Electronics operates across semiconductors (memory, logic chips, foundry services), displays (flexible OLED, quantum dot), consumer electronics (TVs, appliances), and mobile (Galaxy smartphones, tablets, wearables).
Dutch health technology company with €17B revenue; MRI/CT imaging and patient monitoring managing massive sleep apnea device recall competing with Siemens Healthineers and GE HealthCare.
Philips is a Dutch multinational technology and health technology company that has transformed from a broad consumer electronics conglomerate into a focused health technology leader — producing diagnostic imaging systems (MRI, CT, ultrasound), patient monitoring, hospital informatics, personal health products (electric toothbrushes, shavers, sleep apnea devices), and health informatics solutions. Listed on the Amsterdam Stock Exchange (AEX: PHIA) and headquartered in Amsterdam, Philips generates approximately €17 billion ($18 billion) in annual revenue after divesting its lighting division (now Signify) and domestic appliances business.\n\nPhilips' health technology portfolio spans two segments: Diagnosis & Treatment (imaging systems, image-guided therapy, and ultrasound for hospitals) and Connected Care (patient monitoring, respiratory care, sleep therapy). The Diagnosis & Treatment segment provides MRI systems, CT scanners, and X-ray equipment to hospitals globally. The Connected Care segment includes Philips' DreamStation and other sleep apnea (CPAP/BiPAP) devices, home respiratory care, and hospital patient monitoring platforms.\n\nIn 2025, Philips is managing the severe consequences of a 2021 recall of approximately 5.5 million sleep apnea devices (Philips Respironics DreamStation and related models) due to concerns that degraded polyester foam could release harmful particles and gases — one of the largest medical device recalls in history. The recall has resulted in multi-billion dollar settlements, regulatory scrutiny, and significant reputation damage in the sleep therapy market, allowing competitors ResMed and Fisher & Paykel to gain share. Philips' 2025 strategy focuses on resolving recall liabilities, rebuilding the sleep therapy business, and investing in AI-powered diagnostic imaging to compete with Siemens Healthineers and GE HealthCare.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.